Actively Recruiting
Depression, Aging, Stress and Heart Health Study
Led by University of North Carolina, Chapel Hill · Updated on 2025-12-22
30
Participants Needed
1
Research Sites
188 weeks
Total Duration
On this page
Sponsors
U
University of North Carolina, Chapel Hill
Lead Sponsor
F
Foundation of Hope, North Carolina
Collaborating Sponsor
AI-Summary
What this Trial Is About
Depression is a known risk factor for cardiovascular disease (CVD), and this comorbidity contributes significantly to the morbidity and mortality of women. The menopausal transition or perimenopause is a period of vulnerability for both depression and CVD, making it a key time to study this critical public health issue. This research will preliminarily explore whether disruption in two novel stress pathways 1) the renin-angiotensin-aldosterone system (RAAS) and autonomic nervous system (ANS) and their relationship may underlie the link between these illnesses. Findings will provide important insight into potential mechanisms by which depression during perimenopause may increase risk for CVD in midlife women, which will inform potential risk reduction and treatment strategies that can improve health outcomes in this population.
CONDITIONS
Official Title
Depression, Aging, Stress and Heart Health Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 44 to 55 years in the late perimenopause reproductive phase, defined by menstrual cycle history with at least 60 days but less than 1 year of amenorrhea
- Participants may be on antidepressant medications if doses have been stable for at least 30 days prior to participation
You will not qualify if you...
- History of bipolar disorder or primary psychotic disorder
- Prior history of depression in the non-perimenopausal depression group
- Current severe depressive symptoms in the perimenopausal depression group (CES-D score >25)
- Current alcohol or substance use disorder
- Current suicidal ideation with intent or suicide attempt within the past 2 years
- Use of hormonal agents within the past 30 days
- Use of oral, inhaled, or injected steroids within the past 90 days
- Use of blood pressure medications within the past 90 days
- Use of antihistamines within the past 2 weeks
- Use of other medications impacting the RAAS as determined by the study team
- Current cigarette or nicotine use
- Current diagnosis of cardiovascular disease, type I or II diabetes, or other medical conditions affecting study outcomes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27514
Actively Recruiting
Research Team
M
Margo Nathan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here